Join our daily newsletter At The Bell to receive exclusive market insights
Clarity Pharmaceuticals (ASX:CU6) has seen its share price rise more than 15% after signing a commercial-scale agreement with medical tech company Nusano for the supply of copper 64 – also known as Cu-64 or 64Cu isotopes.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
This will boost Clarity’s current network of U.S. suppliers for the diagnostic isotope, as the company progresses late-stage clinical trials and works towards commercialisation of its Targeted Copper Theranostics (TCTs).
Nusano is capable of producing 1,000 Ci (37,000 GBq) of copper-64 per day at capacity from its facility in Utah, translating into more than 18,000 patient doses per day at 200 MBq per dose, with a 48-hour shelf-life. This is far in excess of commercial-scale demands across multiple large indications.
Executive chairperson Dr Alan Taylor said the agreement was an important step for the company. “The signing of this Supply Agreement with Nusano will complement Clarity’s existing network of U.S.-based copper-64 suppliers, providing capacity to ensure abundant and seamless supply of the isotope,” he said.
“As Clarity is generating exceptional data in a number of late-stage clinical trials, we now also have a cost-effective, large-scale supply strategy locked in for the commercial roll-out
of our Targeted Copper Theranostics in the largest healthcare market in the world, the U.S.”
More market news
Kowtow: “Biggest day in financial history” on Trump’s tariffs retreat
Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst
He continued: “This agreement is an important part of a larger commercial manufacturing strategy, which we will continue implementing as we get closer to the filing of New Drug Applications with the US FDA.”
CU6 shares traded at $1.94 – a rise of 15.63% since the market opened.
Join the discussion: See what HotCopper users are saying about Clarity Pharmaceuticals and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
